Sign In
Buy IDXX
IDEXX Laboratories Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $3.41 |
| EPS actual | $3.47 |
| EPS Surprise | 1.76% |
| Revenue estimate | 1.119B |
| Revenue actual | 1.141B |
| Revenue Surprise | 2.00% |
| Release date | Feb 02, 2026 |
| EPS estimate | $2.93 |
| EPS actual | $3.08 |
| EPS Surprise | 5.12% |
| Revenue estimate | 1.073B |
| Revenue actual | 1.091B |
| Revenue Surprise | 1.67% |
| Release date | Nov 03, 2025 |
| EPS estimate | $3.14 |
| EPS actual | $3.40 |
| EPS Surprise | 8.28% |
| Revenue estimate | 1.073B |
| Revenue actual | 1.105B |
| Revenue Surprise | 2.98% |
| Release date | Aug 04, 2025 |
| EPS estimate | $3.28 |
| EPS actual | $3.63 |
| EPS Surprise | 10.67% |
| Revenue estimate | 1.062B |
| Revenue actual | 1.109B |
| Revenue Surprise | 4.43% |
Last 4 Quarters for IDEXX Laboratories
Below you can see how IDXX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 04, 2025 |
| Price on release | $682.78 |
| EPS estimate | $3.28 |
| EPS actual | $3.63 |
| EPS surprise | 10.67% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $573.07 |
| Jul 30, 2025 | $572.09 |
| Jul 31, 2025 | $534.31 |
| Aug 01, 2025 | $535.54 |
| Aug 04, 2025 | $682.78 |
| Aug 05, 2025 | $641.94 |
| Aug 06, 2025 | $624.19 |
| Aug 07, 2025 | $650.06 |
| Aug 08, 2025 | $658.06 |
| 4 days before | 19.14% |
| 4 days after | -3.62% |
| On release day | -5.98% |
| Change in period | 14.83% |
| Release date | Nov 03, 2025 |
| Price on release | $722.94 |
| EPS estimate | $3.14 |
| EPS actual | $3.40 |
| EPS surprise | 8.28% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $634.36 |
| Oct 29, 2025 | $627.66 |
| Oct 30, 2025 | $628.54 |
| Oct 31, 2025 | $629.51 |
| Nov 03, 2025 | $722.94 |
| Nov 04, 2025 | $722.12 |
| Nov 05, 2025 | $720.21 |
| Nov 06, 2025 | $713.74 |
| Nov 07, 2025 | $708.45 |
| 4 days before | 13.96% |
| 4 days after | -2.00% |
| On release day | -0.113% |
| Change in period | 11.68% |
| Release date | Feb 02, 2026 |
| Price on release | $639.60 |
| EPS estimate | $2.93 |
| EPS actual | $3.08 |
| EPS surprise | 5.12% |
| Date | Price |
|---|---|
| Jan 27, 2026 | $694.75 |
| Jan 28, 2026 | $687.74 |
| Jan 29, 2026 | $676.71 |
| Jan 30, 2026 | $670.46 |
| Feb 02, 2026 | $639.60 |
| Feb 03, 2026 | $632.56 |
| Feb 04, 2026 | $642.94 |
| Feb 05, 2026 | $643.59 |
| Feb 06, 2026 | $644.61 |
| 4 days before | -7.94% |
| 4 days after | 0.783% |
| On release day | -1.10% |
| Change in period | -7.22% |
| Release date | May 05, 2026 |
| Price on release | $562.97 |
| EPS estimate | $3.41 |
| EPS actual | $3.47 |
| EPS surprise | 1.76% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $553.66 |
| Apr 30, 2026 | $560.80 |
| May 01, 2026 | $567.46 |
| May 04, 2026 | $563.12 |
| May 05, 2026 | $562.97 |
| May 06, 2026 | $579.23 |
| May 07, 2026 | $572.20 |
| May 08, 2026 | $560.11 |
| May 11, 2026 | $532.00 |
| 4 days before | 1.68% |
| 4 days after | -5.50% |
| On release day | 2.89% |
| Change in period | -3.91% |
IDEXX Laboratories Earnings Call Transcript Summary of Q1 2026
IDEXX reported a strong start to FY2026 with Q1 revenue up 14% reported and 11% organic, led by companion animal group (CAG) diagnostics recurring revenue which grew ~11% organically. Instrument revenue rose 28% organically with 1,100 inVue Dx placements in the quarter (tracking to a 2026 target of ~5,500). VetLab consumables, Reference Labs, software and imaging all showed healthy growth; Cancer DX adoption continues to expand domestically and internationally. Q1 operating margin expanded ~100 basis points (gross margin 63.4%), comparable EPS rose 15% to $3.47, and free cash flow was $234 million (T12M conversion ~99%). Management raised full-year revenue guidance to $4.675B–$4.76B (organic growth 7.7%–9.7%) and raised EPS guidance to $14.45–$14.90, citing continued commercial execution, innovation-driven volume, and modestly improved visit trends (U.S. clinical visits guide ~-1.5% for the year). Company highlighted ongoing controlled rollout of inVue Dx F&A with broader launch planned later in 2026, continued rollouts of Cancer DX internationally, accelerated software/cloud adoption and AI priorities. Leadership transition: Jay Mazelsky will move to Executive Chair and Mike Erickson becomes CEO. Balance sheet remains strong (net leverage ~0.5x) with ongoing share repurchases and capex ~ $180M for the year.
